RTL
IOVA icon

Red Tortoise LLC’s Iovance Biotherapeutics IOVA Stock Holding History

Red Tortoise LLC’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-195
Closed -$1.19K – 588
2023
Q1 		$1.19K Buy
+195
New +$1.34K ﹤0.01% 524

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Red Tortoise LLC's IOVA Position: Q2 2023 in Review

Red Tortoise LLC sold out of Iovance Biotherapeutics (IOVA) in Q2 2023, closing a stake of 195 shares — an estimated $1.19K sold.

Red Tortoise LLC first reported a position in IOVA in Q1 2023 and held it in 1 quarter. The position peaked at $1.19K in Q1 2023. 219 funds tracked by Wall St. Rank hold IOVA as of Q2 2023.

  • Red Tortoise LLC reported no remaining Iovance Biotherapeutics position as of Q2 2023 after selling out during the quarter.
  • Red Tortoise LLC sold 195 Iovance Biotherapeutics shares in Q2 2023, an estimated $1.19K.
  • Red Tortoise LLC first reported a position in Iovance Biotherapeutics in Q1 2023 and held it in 1 quarter.
  • Red Tortoise LLC's Iovance Biotherapeutics position peaked at $1.19K in Q1 2023.
  • 219 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2023.

Based on Red Tortoise LLC's 13F filing for Q2 2023, filed 26 Jul 2023.